360 related articles for article (PubMed ID: 9930730)
1. Role of protein kinase C (PKC) in agonist-induced mu-opioid receptor down-regulation: I. PKC translocation to the membrane of SH-SY5Y neuroblastoma cells is induced by mu-opioid agonists.
Kramer HK; Simon EJ
J Neurochem; 1999 Feb; 72(2):585-93. PubMed ID: 9930730
[TBL] [Abstract][Full Text] [Related]
2. Role of protein kinase C (PKC) in agonist-induced mu-opioid receptor down-regulation: II. Activation and involvement of the alpha, epsilon, and zeta isoforms of PKC.
Kramer HK; Simon EJ
J Neurochem; 1999 Feb; 72(2):594-604. PubMed ID: 9930731
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells.
Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL
J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156
[TBL] [Abstract][Full Text] [Related]
4. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.
Breivogel CS; Selley DE; Childers SR
J Neurochem; 1997 Apr; 68(4):1462-72. PubMed ID: 9084416
[TBL] [Abstract][Full Text] [Related]
5. Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells.
Baumhaker Y; Gafni M; Keren O; Sarne Y
Mol Pharmacol; 1993 Aug; 44(2):461-7. PubMed ID: 8394999
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma Neuro2A cells stably expressing a cloned mu-opioid receptor: a specific cellular model to study acute and chronic effects of morphine.
Chakrabarti S; Law PY; Loh HH
Brain Res Mol Brain Res; 1995 Jun; 30(2):269-78. PubMed ID: 7637578
[TBL] [Abstract][Full Text] [Related]
7. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
8. Internalization and down-regulation of mu opioid receptors by endomorphins and morphine in SH-SY5Y human neuroblastoma cells.
Horner KA; Zadina JE
Brain Res; 2004 Dec; 1028(2):121-32. PubMed ID: 15527737
[TBL] [Abstract][Full Text] [Related]
9. Distinct differences between morphine- and [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin-mu-opioid receptor complexes demonstrated by cyclic AMP-dependent protein kinase phosphorylation.
Chakrabarti S; Law PY; Loh HH
J Neurochem; 1998 Jul; 71(1):231-9. PubMed ID: 9648870
[TBL] [Abstract][Full Text] [Related]
10. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
11. Tolerance to mu-opioid agonists in human neuroblastoma SH-SY5Y cells as determined by changes in guanosine-5'-O-(3-[35S]-thio)triphosphate binding.
Elliott J; Guo L; Traynor JR
Br J Pharmacol; 1997 Aug; 121(7):1422-8. PubMed ID: 9257923
[TBL] [Abstract][Full Text] [Related]
12. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
13. Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells.
Zadina JE; Chang SL; Ge LJ; Kastin AJ
J Pharmacol Exp Ther; 1993 Apr; 265(1):254-62. PubMed ID: 8097244
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase A maintains cellular tolerance to mu opioid receptor agonists in hypothalamic neurosecretory cells with chronic morphine treatment: convergence on a common pathway with estrogen in modulating mu opioid receptor/effector coupling.
Wagner EJ; Rønnekleiv OK; Kelly MJ
J Pharmacol Exp Ther; 1998 Jun; 285(3):1266-73. PubMed ID: 9618432
[TBL] [Abstract][Full Text] [Related]
15. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
Pak Y; Kouvelas A; Scheideler MA; Rasmussen J; O'Dowd BF; George SR
Mol Pharmacol; 1996 Nov; 50(5):1214-22. PubMed ID: 8913353
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling.
Yabaluri N; Medzihradsky F
Mol Pharmacol; 1997 Nov; 52(5):896-902. PubMed ID: 9351981
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profiles of selective non-peptidic delta opioid receptor ligands.
Chaturvedi K; Jiang X; Christoffers KH; Chinen N; Bandari P; Raveglia LF; Ronzoni S; Dondio G; Howells RD
Brain Res Mol Brain Res; 2000 Sep; 80(2):166-76. PubMed ID: 11038249
[TBL] [Abstract][Full Text] [Related]
18. Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.
Spivak CE; Beglan CL; Seidleck BK; Hirshbein LD; Blaschak CJ; Uhl GR; Surratt CK
Mol Pharmacol; 1997 Dec; 52(6):983-92. PubMed ID: 9415708
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of gamma-hydroxybutyrate on mu, delta and kappa opioid receptor binding.
Feigenbaum JJ; Simantov R
Neurosci Lett; 1996 Jul; 212(1):5-8. PubMed ID: 8823749
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment with protein kinase C activator phorbol 12,13-dibutyrate attenuates the antinociception induced by mu- but not epsilon-opioid receptor agonist in the mouse.
Narita M; Ohsawa M; Mizoguchi H; Kamei J; Tseng LF
Neuroscience; 1997 Jan; 76(1):291-8. PubMed ID: 8971779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
